Drug Profile
Parsatuzumab - Genentech
Alternative Names: Anti-EGFL7 - Genentech; M-444A; M0444A; MEGF-0444A; RG-7414; RO-5490248Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Genentech
- Developer Chugai Pharmaceutical; Genentech
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action EGFL7 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Colorectal cancer; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 17 Oct 2013 Discontinued - Phase-I for Solid tumours (combination therapy, late-stage disease, second-line therapy or greater) in USA (IV)
- 17 Oct 2013 Discontinued - Phase-I for Solid tumours (monotherapy) in USA (IV)
- 17 Oct 2013 Discontinued - Phase-I for Solid tumours in Japan (IV)